Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05117008
Title Maintenance Belantamab Mafodotin (Blenrep) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Medical College of Wisconsin
Indications

multiple myeloma

Therapies

belantamab mafodotin-blmf

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.